ADC With Radiotherapy for Brain Mets Ups Risk of Necrosis

An antibody-drug conjugate given concurrently with stereotactic radiotherapy to treat brain metastases may increase patients' risk for symptomatic radiation necrosis, a study suggests.

Related Keywords

New York ,United States ,Memorial Sloan Kettering Cancer Center ,Emilys Lebow , ,Malignant Head And Neck Neoplasm ,Brain Metastasis ,Metastatic Brain Tumor ,Radiosurgery ,Tereotactic Radiotherapy ,Radiation Oncology ,Brain ,Radiation Necrosis ,Metastasis ,Biologic Therapy ,Hodgkins Lymphoma ,Antibody Drug Conjugates Adcs ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Humanized Monoclonal Antibody ,Ev ,